EP0716657A1 - $g(b)-CARBOLINES A SUBSTITUTION ALCOXY AGISSANT SUR LE RECEPTEUR D'AMPA - Google Patents

$g(b)-CARBOLINES A SUBSTITUTION ALCOXY AGISSANT SUR LE RECEPTEUR D'AMPA

Info

Publication number
EP0716657A1
EP0716657A1 EP94925339A EP94925339A EP0716657A1 EP 0716657 A1 EP0716657 A1 EP 0716657A1 EP 94925339 A EP94925339 A EP 94925339A EP 94925339 A EP94925339 A EP 94925339A EP 0716657 A1 EP0716657 A1 EP 0716657A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
formula
alkoxy
compounds
carboline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94925339A
Other languages
German (de)
English (en)
Inventor
Dieter Seidelmann
Lechoslaw Turski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0716657A1 publication Critical patent/EP0716657A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to alkoxy- ⁇ -carboline derivatives, their production and use in medicaments and intermediates for the production thereof.
  • the compounds of the formula I act on the modulation site of the AMPA receptor or on AMPA receptor-dependent ion channels and correct the pathologically changed function of this receptor.
  • the synaptic function of the excitatory amino acid L-glutamate is mediated primarily via AMPA receptors.
  • Increased or decreased glutamatergic neurotransmission in the central nervous system leads to numerous neurological and psychiatric diseases.
  • the compounds of the formula I are therefore suitable for the production of medicaments for the symptomatic and preventive treatment of neurological and psychiatric diseases.
  • the invention relates to the compounds of formula I.
  • C * -.6-alkanoyloxy may be substituted, or - (CH2) n -CO- (CH2) m - means n, m is 1, 2 or 3,
  • Rl and R2 are the same or different and are hydrogen, C- ⁇ 4-alkyl, Cß. Cycloalkyl,
  • B is a direct bond, oxygen, sulfur,> CH-R 5 ,> COH-R 5 or> NR 5 and
  • Y means oxygen, sulfur or> NH
  • R 3 is hydrogen, COOH, COO-Cj.g-alkyl, CO-R 6 or an optionally one to three times with C ⁇ -4-alkyl, C3_7-cycloalkyl, halogen, C ⁇ _4-alkoxy-C- _2-alkyl, C- _4-alkoxy, phenyl or amino-substituted C6_i2-aryl or hetaryl radical,
  • R 4 is hydrogen, C - ⁇ - alkyl, C ⁇ _4-alkoxy-C 1 _ 2 alkyl and
  • the invention encompasses all possible stereoisomers such as enantiomers and diastereomers as well as their mixtures and racemates.
  • the substituent can be in the A-ring in position 5-8, preferably in the 5- or 6-position.
  • Straight-chain or branched C- _5-alkylene is, for example, methylene, ethylene, propylene, isopropylidene, 1-methylethylene, 2-ethylpropylene, 2,2-dimethylethylene, 1,1-dimethylethylene, 1,2-dimethylethylene, tetramethylene.
  • the substituent of the alkylene radical A is in any position, preferably in the 2,3 or 4 position of the straight-chain alkylene radical.
  • Alkyl contains both straight and branched chain residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl, hexyl, 2,2-dimethylpropyl and 2-methylbutyl.
  • Cycloalkyl can each represent cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and 2-methylcyclopropyl.
  • Cyclopropylmethyl and cyclohexylmethyl are examples of cycloalkylalkyl radicals.
  • the phenyl-C- [ _2-alkyl substituent can in each case be straight-chain or branched in the alkyl radical, such as, for example, benzyl, phenethyl, ⁇ -methylbenzyl.
  • Halogen is fluorine, chlorine, bromine and iodine.
  • the pyridine residue R ⁇ is bound in position 2, 3 or 4.
  • the aryl and hetaryl radical R 3 can be present as a mono- or bicyclic radical and contain 5-12 ring atoms, preferably 5-9 ring atoms, such as, for example, phenyl, biphenyl, naphthyl, indenyl as aryl radical and thienyl, furyl, pyranyl, pyrrolyl, pyrazolyl, pyridyl , Pyrimidinyl, pyridazinyl, oxazolyl, iso-oxazolyl, thiazolyl, isothiazolyl, 1,3,4-oxadiazol-2-yl, l, 2,4-oxadiazol-5-yl, l, 2,4-oxadiazol-3-yl , Quinolyl, isoquinolyl, benzo [l] thienyl, benzofuryl as a hetaryl radical with 1-3 heteroatoms such as sulfur, oxygen and / or nitrogen.
  • Preferred heteroaryl radicals R 3 are isoxazol-3-yl, isoxazol-5-yl, l, 2,4-oxadiazol-5-yl, l, 2,4-oxadiazol-3-yl, l, 3,4-oxadiazol- 2-yl, thiazol-4-yl, thiazol-2-yl, pyrrol-2-yl, pyrrol-3-yl, 2-thienyl, 3-thienyl, pyridin-2-yl, pyridin-3-yl, pyridine- 4-yl and oxazol-5-yl called, which may optionally be substituted.
  • Preferred aryl R 3 is phenyl optionally substituted with halogen or CL- alkoxy.
  • a bicycloalkyl radical R * - ' is to be understood as bicyloheptyl and bicyclooctyl.
  • Examples of mono- or bicyclic aryl radical R ⁇ are phenyl, biphenyl, naphthyl and indenyl.
  • the C 6 alkanoyl radical is derived in each case from straight-chain or branched ahphatic carboxylic acids, such as, for example, formic acid, acetic acid, propionic acid, butyric acid,
  • Trimethyl acetic acid or caproic acid Trimethyl acetic acid or caproic acid.
  • Suitable sulfonic acid residues R ⁇ are the known benzenesulfonic acids, which can be substituted by halogen or C 1-4 alkyl, and C - ⁇ alkanesulfonic acids, such as methanesulfonic acid, p-toluenesulfonic acid.
  • the physiologically compatible salts are derived from inorganic and organic acids.
  • Inorganic acids such as, for example, hydrohalic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid or organic acids such as, for example, aliphatic or aromatic mono- or dicarboxylic acids such as formic acid, acetic acid, maleic acid, fumaric acid, succinic acid, lactic acid, tartaric acid, citric acid or oxalic acid, sulfonic acid, glycated acid, glycated acid, for example, -C-4-alkanesulfonic acids such as methanesulfonic acid or optionally substituted by halogen or -CC-alkyl substituted benzenesulfonic acids such as p-toluenesulfonic acid.
  • R 3 is hydrogen, COOH, COOC - [_ 6-alkyl or an optionally one to three times with C ⁇ _4-alkyl, C 3 _7-cycloalkyl, halogen, C ⁇ _4-alkoxy, C - ⁇ - alkoxy-C - ⁇ .
  • R 4 , R ⁇ and A have the above meaning.
  • A denotes straight-chain or branched C- _5-alkylene, which can be substituted by hydroxy or CJ. ⁇ - alkoxy, Rl and R2 together with the nitrogen atom form the heterocycle
  • R9 is hydrogen or C - [_ 6-alkyl
  • R 3 is hydrogen, COOH or COOC- ⁇ g-alkyl and their stereoisomers and
  • R-5 is a phenyl, benzyl, benzoyl, ⁇ -hydroxybenzyl, phenethyl, 2-oxo-2-phenethyl or l-oxo-2-phenethyl radical which is substituted, then halogen and C1-.
  • R 3 , R 4 and R ⁇ have the above meaning, with an amine of the formula EI
  • R 3 , R 4 and R ⁇ have the above meaning and X represents a leaving group with an amine of the formula V.
  • R - * and R- ⁇ have the above meaning, and if desired then subsequently introduces or cleaves the substituent R ⁇ or forms the physiologically tolerable salts or converts the physiologically tolerated salts into the free compounds of the formula I or separates racemates.
  • the nucleophilic substitution of the leaving group X according to process variants a) and b) is carried out according to the usual methods in an organic solvent which is inert under the reaction conditions under basic conditions.
  • Halogens such as chlorine, bromine or iodine or organic sulfonic acid residues such as the rest of an alkanesulfonic acid, for example mesylate, triflate or the rest of an aromatic sulfonic acid, for example toluenesulfonic acid or bromobenzenesulfonic acid, are suitable as escape groups X.
  • Suitable inert organic solvents are polar solvents such as dimethylformamide, dimethylacetamide or alcohols such as ethanol, methanol or cyclic ethers such as dioxane, tetrahydrofuran, halogenated hydrocarbons, aromatic hydrocarbons or mixtures of the solvents mentioned.
  • inorganic and organic bases are suitable as bases.
  • inorganic bases are alkali or alkaline earth metal hydroxide, carbonates, bicarbonates or alcoholates.
  • organic bases are tertiary organic amines such as tripropylamine, triethylamine, N-alkylmorpholine or N-alkylpiperidine. However, it can also an excess of the amine of formula V can be used as the base or the
  • the reaction temperature can be between 0 ° C and the boiling point of the solvent.
  • the R 1 substituent can be introduced by the customary alkylation, benzylation and sulfonylation processes, for example by using a reactive one
  • the substituent R ⁇ is split off in the usual way, depending on the nature of the substituent, in a basic or hydrogenolytic manner.
  • the compounds of the formula I can be isolated from the reaction mixture and purified in a manner known per se.
  • Acid addition salts can be converted into the free bases in a conventional manner and, if desired, these can be converted into physiologically compatible acid addition salts in a known manner, for example by adding a concentrated solution of the desired acid to the solution.
  • the optically active compounds can be obtained from the racemates starting from optically active starting compounds or in a manner known per se.
  • the enantiomers can be separated, for example, by chromatography on optically active support materials, by reaction with optically active acids and subsequent fractional crystallization.
  • the invention also includes the compounds of formula IV
  • the compounds of the formula IV are prepared by processes known per se, for example by
  • a and X have the meaning given above and Y is a refugee group, etherified or
  • the groups mentioned under X are suitable as escape group Y.
  • the etherification is carried out in the usual way in the presence of bases. Escape group X is introduced using customary methods.
  • the hydroxy derivatives of the formula II can be prepared according to EP-A-130 140, EP 0161 574, EP 0305 322, WO 92/21679 and WO92 / 22549.
  • the compounds of the formula I and their physiologically tolerable salts can be used as medicaments because of their action on the modulation site of the quisqualate receptor or the quisqualate receptor-dependent ion channel.
  • mice Male NMRI mice weighing 18-22 g with were kept under controlled conditions (6 -18 00 0 ° clock light / dark cycle, with free access to food and water) and their assignment to groups was randomized. The groups consisted of 5 - 16 animals. The animals were observed between 8 a.m. and 1 p.m.
  • AMPA was injected into the left ventricle by freely moving mice.
  • the applicator consisted of a cannula with a stainless steel device that limits the depth of the injection to 3.2 mm.
  • the applicator was connected to an injection pump.
  • the injection needle was inserted perpendicular to the surface of the skull according to the coordinates of Montemurro and Dukelow.
  • the animals were up to 180 see until the appearance of clonic or tonic cramps. observed.
  • the clonic movements that are longer than 5 see. persist were counted as convulsions.
  • the beginning of the clonic convulsions was used as the end point for the determination of the convulsive threshold.
  • the dose required to increase or decrease the seizure threshold by 50% (THRD50) was determined in 4-5 experiments.
  • the THRD50 and the confidence limit were determined in a regression analysis.
  • Treatment with the compounds according to the invention prevents or delays the cell damage and functional disorders which occur as a result of the disease and reduces the symptoms which arise as a result.
  • the diseases which can be triggered by the dysfunction of excitatory amino acids or altered glutamate neurotransmission include, for example neurodegenerative diseases such as Parkinson's disease, Huntington's disease, Alzheimer's disease, senile dementia, multi-infarct dementia, amyotrophic lateral sclerosis, olivoponto cerebellar degeneration, epilepsy; Cell damage from hypoglycemia, hypoxia, ischemia and disorders of energy metabolism; neuronal damage caused by brain damage such as stroke, brain trauma and asphyxia, as well as psychoses, schizophrenia, anxiety, pain, migraines and vomiting.
  • neurodegenerative diseases such as Parkinson's disease, Huntington's disease, Alzheimer's disease, senile dementia, multi-infarct dementia, amyotrophic lateral sclerosis, olivoponto cerebellar degeneration, epilepsy
  • Cell damage from hypoglycemia, hypoxia, ischemia and disorders of energy metabolism neuronal damage caused by brain damage such as stroke, brain trauma and asphyxia, as well as
  • Functional disorders such as memory disorders (amnesia), disorders of the learning process, vigilance symptoms and withdrawal symptoms after chronic use of addictive substances such as sedative drugs, hallucinogens, alcohol, cocaine and opiates are based on the dysfunction of glutamaterergic neurotransmission.
  • addictive substances such as sedative drugs, hallucinogens, alcohol, cocaine and opiates are based on the dysfunction of glutamaterergic neurotransmission.
  • the indications can be shown by conventional pharmacological tests.
  • the invention also encompasses pharmaceutical compositions which contain the compounds mentioned, their preparation and the use of the compounds according to the invention for the preparation of medicaments which are used for the treatment and prophylaxis of the abovementioned diseases.
  • the medicaments are produced by methods known per se by bringing the active ingredient into the form of a pharmaceutical preparation with suitable carriers, auxiliaries and / or additives which is suitable for enteral or parenteral administration.
  • the application can take place orally or sublingually as a solid in the form of capsules or tablets or as a liquid in the form of solutions, suspensions, elixirs or emulsions or rectally in the form of suppositories or in the form of injection solutions which may also be used subcutaneously.
  • auxiliaries for the desired pharmaceutical formulation are the inert organic and inorganic carrier materials known to those skilled in the art, such as, for example, water, gela jine, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • inert organic and inorganic carrier materials such as, for example, water, gela jine, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • con - Serving, stabilizing, wetting agents, emulsifiers or salts to change the osmotic pressure or buffer are included.
  • the pharmaceutical preparations can be in solid form, for example as tablets, dragées, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions.
  • Auxiliaries close to the surface such as salts of bile acids or animal or vegetable phospholipids, but also mixtures thereof and liposomes or their components can also be used as carrier systems.
  • Tablets, coated tablets or capsules with talc and / or hydrocarbon carriers or binders, such as lactose, corn or potato starch, are particularly suitable for oral use. It can also be used in liquid form, for example as juice, to which a sweetener may be added.
  • Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
  • the dosage of the active ingredients can vary depending on the type of application, age and weight of the patient, type and severity of the disease to be treated and similar factors.
  • the daily dose can be given as a single dose to be administered once or divided into 2 or more daily doses.
  • the compounds are introduced in a dose unit of 0.05 to 500 mg of active substance in a physiologically acceptable carrier. Generally a dose of 0.1 to 1000 mg day (0.001 to 10 mg / kg), preferably 0.1 to 100 mg / day is used.
  • the (4-fluorophenyl) -l [l- (3-methylsulfonyloxypropyl) -4-piperidyl] ketone is obtained according to methods known from the literature by alkylation of 4- (4-fluorobenzoyl) piperidine with 3-bromopropanol-1 and potassium carbonate in dimethylformamide and subsequent reaction with methanesulfonic acid and triethylamine in methylene chloride.
  • the 5- (3-chloropropoxy) -4-methoxymethyl-ß-carboline-3-carboxylic acid isopropyl ester required as starting material (melting point 178-180 ° C.) is obtained by etherification of 5-hydroxy-4-methoxymethyl-ß-carboline-3-carboxylic acid isopropyl ester with l-bromo-3-chloropropane and potassium carbonate in dimethylformamide.
  • the 4-methoxymethyl-5- (2,3-epoxypropoxy) -ß-carboline-3-carboxylic acid isopropyl ester is obtained by methods known from the literature by etherification of 5-hydroxy-4-methoxymethyl-ß-carboline-3-carboxylic acid isopropyl ester with epichlorohydrin and potassium carbonate in Dimethylformamide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne les composés de la formule (I) ainsi que leur préparation et leur utilisation dans des médicaments agissant sur le récepteur d'AMPA.
EP94925339A 1993-08-31 1994-08-29 $g(b)-CARBOLINES A SUBSTITUTION ALCOXY AGISSANT SUR LE RECEPTEUR D'AMPA Withdrawn EP0716657A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4330175A DE4330175A1 (de) 1993-08-31 1993-08-31 Alkoxy-substituierte beta-Carboline
DE4330175 1993-08-31
PCT/DE1994/001009 WO1995006647A1 (fr) 1993-08-31 1994-08-29 β-CARBOLINES A SUBSTITUTION ALCOXY AGISSANT SUR LE RECEPTEUR D'AMPA

Publications (1)

Publication Number Publication Date
EP0716657A1 true EP0716657A1 (fr) 1996-06-19

Family

ID=6497015

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94925339A Withdrawn EP0716657A1 (fr) 1993-08-31 1994-08-29 $g(b)-CARBOLINES A SUBSTITUTION ALCOXY AGISSANT SUR LE RECEPTEUR D'AMPA

Country Status (17)

Country Link
EP (1) EP0716657A1 (fr)
JP (1) JPH09501938A (fr)
KR (1) KR960704888A (fr)
CN (1) CN1129938A (fr)
AU (1) AU7530394A (fr)
CA (1) CA2170615A1 (fr)
CZ (1) CZ50596A3 (fr)
DE (1) DE4330175A1 (fr)
FI (1) FI960940A0 (fr)
HU (1) HUT73845A (fr)
IL (1) IL110745A0 (fr)
NO (1) NO960812L (fr)
NZ (1) NZ271615A (fr)
PL (1) PL313230A1 (fr)
SK (1) SK23896A3 (fr)
WO (1) WO1995006647A1 (fr)
ZA (1) ZA946670B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
IL283725B2 (en) 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
EP3866794B1 (fr) 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Procédés de traitement de maladies rhumatismales à l'aide de composés à base de trimétazidine
EP3976101A4 (fr) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. Méthodes de traitement de la fibrose faisant appel à des composés favorisant l'oxydation du glucose
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57123180A (en) * 1980-12-17 1982-07-31 Schering Ag 3-substituted beta-carboline, manufacture and psychotropic drug containing same
DE3545776A1 (de) * 1985-12-20 1987-06-25 Schering Ag 5-aminoalkyl-ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
DE3608089A1 (de) * 1986-03-08 1987-09-10 Schering Ag Heteroaryl-oxy-ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
AU619203B2 (en) * 1987-08-28 1992-01-23 Schering Aktiengesellschaft Isoxazole-beta-carboline derivatives
DE3943225A1 (de) * 1989-12-23 1991-06-27 Schering Ag Neue ss-carboline, verfahren zu deren herstellung und deren verwendung in arzneimitteln
US5350750A (en) * 1991-04-27 1994-09-27 Schering Aktiengesellschaft β-carboline-3-hydroxyalkylcarboxylic acid ester derivatives, process for their production and their use in pharmaceutical agents
DE4118741A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue hetaryloxy-(beta)-carboline, deren herstellung und verwendung in arzneimitteln
DE4120109A1 (de) * 1991-06-15 1992-12-17 Schering Ag 3-aryl- oder 3-hetaryl-(beta)-carboline, deren herstellung und verwendung in arzneimitteln
DE4130933A1 (de) * 1991-09-13 1993-03-18 Schering Ag Neue (beta)-carbolinderivate, deren herstellung und verwendung in arzneimitteln
DE4212529A1 (de) * 1992-04-10 1993-10-14 Schering Ag Verwendung von µ-Carbolinen als nicht-kompetitive Glutamat-Antagonisten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9506647A1 *

Also Published As

Publication number Publication date
NO960812D0 (no) 1996-02-28
FI960940L (fi) 1996-02-28
NZ271615A (en) 1996-09-25
IL110745A0 (en) 1994-11-11
CZ50596A3 (en) 1996-06-12
NO960812L (no) 1996-02-28
CA2170615A1 (fr) 1995-03-09
WO1995006647A1 (fr) 1995-03-09
HUT73845A (en) 1996-09-30
FI960940A7 (fi) 1996-02-28
PL313230A1 (en) 1996-06-10
FI960940A0 (fi) 1996-02-28
KR960704888A (ko) 1996-10-09
JPH09501938A (ja) 1997-02-25
SK23896A3 (en) 1996-11-06
CN1129938A (zh) 1996-08-28
HU9600505D0 (en) 1996-04-29
DE4330175A1 (de) 1995-03-02
ZA946670B (en) 1995-04-21
AU7530394A (en) 1995-03-22

Similar Documents

Publication Publication Date Title
CN116615427B (zh) 被取代的大环化合物及相关治疗方法
DE69231395T2 (de) Neue medizinische Indikation für Tachykinin-Antagonisten
DE60215132T2 (de) Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
EP0709384B1 (fr) Dérivés de benzylpiperidine ayant une haute affinité pour les sites de liaison de récepteurs d'aminoacides
US20070027118A1 (en) Novel compounds of amino sulfonyl derivatives
DE10217006A1 (de) Substituierte Indole
PL192397B1 (pl) Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna
KR100544295B1 (ko) 에이엠피에이 수용체 활성을 증가시키는 벤조퓨란 화합물
WO1999032481A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
WO1999032489A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
DE4410822A1 (de) Neue Piperidin-Derivate
EP0964863B1 (fr) Oxazolidinones s'utilisant comme 5-ht2a-antagonistes
EP0635505B1 (fr) Dérivés de 4-aryloxy et 4-arylthio-piperidine
DE69031111T2 (de) Indolderivate
EP0716657A1 (fr) $g(b)-CARBOLINES A SUBSTITUTION ALCOXY AGISSANT SUR LE RECEPTEUR D'AMPA
EA011635B1 (ru) Новые производные амида гетероциклической карбоновой кислоты
EP3223821A1 (fr) Dérivés de pyridobenzodiazepinone substitués et leur utilisation
DE60112725T2 (de) Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
DE3421641A1 (de) Indolderivate
WO1999032486A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
DE19602505A1 (de) 1-(Pyrazol-4-Indol-3-yl)-Piperidine
JP2002532480A (ja) モルホリノン及びモルホリン誘導体、ならびにその使用
DE69215886T2 (de) NEUROLEPTISCH 2-SUBSTITUIERTE PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINE
EP0763535B1 (fr) Dérivés de pipéridinylméthyloxazolidin-2-one, leur préparation et leur utilisation comme composés pharmacologiques actifs sur le système nerveux central
EP0443197A2 (fr) Oxazolidinones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19970219